Renalytix to Present at 42nd Annual William Blair Growth Stock Conference
08 June 2022 - 9:00PM
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the
Company will present at the 42nd Annual William Blair Growth Stock
Conference on Thursday, June 9 at 2:00 p.m. CT. Interested parties
may access a live and archived webcast of the presentation on the
“Investors” section of the company website
at investors.renalytix.com.
For further information, please contact:
Renalytix plc |
www.renalytix.com |
|
James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
Alex Price / Nicholas Moore |
|
|
|
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
|
Gary Clarence / Daniel Adams |
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933
8780 or renalytix@walbrookpr.com |
|
Paul McManus / Lianne Applegarth / Alice Woodings |
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
|
|
|
|
CapComm Partners |
Tel: 415-389-6400
or investors@renalytix.com |
|
Peter DeNardo |
|
|
About Renalytix Renalytix
(NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and
laboratory services company that is the global founder and leader
in the new field of bioprognosisTM for kidney health. The
leadership team, with a combined 200+ years of healthcare and
in-vitro diagnostic experience, has designed its KidneyIntelX
laboratory-developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D
with early CKD stages 1-3. We believe that by understanding how
disease will progress, patients and providers can take action early
to improve outcomes and reduce overall health system costs. For
more information, visit www.renalytix.com.
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From May 2023 to May 2024